Status: Not yet recruiting
Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
This is a multicenter, open-label, proof-of-concept, phase Ⅱ adaptive basket clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of LP-005 Injection as add-on therapy to standard treatment in patients with complement-mediated renal diseases.
Participants needed: 46
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Longbio PharmaUpdated: Jan 23, 2026Locations: 1
Eligibility criteria
Males or females aged 18 to 65 years at screening. [+4]
Pregnant or lactating female. [+8]